NVIDIA Pushes AI Into Drug Development With Simulations Plus Collaboration

AI summary

NVIDIA (NasdaqGS:NVDA) has entered a new collaboration with Simulations Plus to apply GPU acceleration and AI-assisted workflows to drug development and quantitative systems pharmacology. The partnership focuses on speeding up complex modeling and simulation tasks that support earlier stage drug discovery and development decisions. This move extends NVIDIA's reach further into life sciences, complementing its existing presence in broader AI and data center computing. NVIDIA, with a recent...